Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Income from Continuing Operations: 2010-2025

Historic Income from Continuing Operations for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to -$3.2 million.

  • Anika Therapeutics' Income from Continuing Operations fell 69.33% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year decrease of 259.09%. This contributed to the annual value of -$10.1 million for FY2024, which is 194.91% down from last year.
  • Anika Therapeutics' Income from Continuing Operations amounted to -$3.2 million in Q3 2025, which was up 31.95% from -$4.7 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Income from Continuing Operations registered a high of $16.2 million during Q4 2023, and its lowest value of -$10.3 million during Q1 2023.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$3.2 million (2025), whereas its average is -$2.3 million.
  • Examining YoY changes over the last 5 years, Anika Therapeutics' Income from Continuing Operations showed a top increase of 411.38% in 2022 and a maximum decrease of 853.99% in 2022.
  • Anika Therapeutics' Income from Continuing Operations (Quarterly) stood at -$3.2 million in 2021, then soared by 411.38% to $10.1 million in 2022, then soared by 60.71% to $16.2 million in 2023, then tumbled by 123.48% to -$3.8 million in 2024, then crashed by 69.33% to -$3.2 million in 2025.
  • Its Income from Continuing Operations was -$3.2 million in Q3 2025, compared to -$4.7 million in Q2 2025 and -$4.0 million in Q1 2025.